Biotech News
BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering
ir.bioxceltherapeutics.com2026-05-06 15:26 EST
NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence to develop transformative medicines in neuroscience, today announced that it has entered into a securities purchase agreement